Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease
United European Gastroenterology Journal · 2023
DOI: 10.1002/ueg2.12455 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift United European Gastroenterology Journal, 2023. Verfasst von Pauline Wils und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Claude Huriez Hospital, University of Lille 2, Lille, France. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims The accumulation of multiple randomized controlled trials in the field of inflammatory bowel diseases provides an opportunity to compare treatment effects between phase 2 and 3 trials. We aimed to determine whether treatment effects observed in phase 3 investigating biologics and small molecule drugs differed from those in their preceding phase 2 trial.
Methods
We first performed a review of phase 2 and phase 3 trials enrolling ulcerative colitis (UC) or Crohn's disease (CD) patients. We compared the percent overall success for key endpoints between phases (several phase 3 could be matched to a single phase 2 trial). Then, we compared the percent overall success in the matched phase 2 and 3 trials (ratio 1:1), and performed sensitivity analysis.
Results
We identified 14 phase 2 (8 CD; 6 UC) and 24 phase 3 (13 CD; 11 UC) trials. In CD, the different analyses suggest that the percentage of overall success of clinical remission and clinical response was significantly higher in phase 2 than in phase 3 trials. In UC, the analyses suggest collectively that the percent of treatment effect seemed similar for clinical remission, clinical response and histologic outcomes between phases but with a lower percentage of overall success in phase 2 than in phase 3 trials for endoscopic endpoints.
Conclusions
In UC, we observed a similar percentage of treatment effect for clinical and histologic outcomes between phase 2 and 3 trials but not for endoscopic outcomes. Whereas in CD, we showed a failure to reproduce similar results between phases. These results may help sponsors in the design of future drug development programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Claude Huriez Hospital, University of Lille 2, Lille, France.
- Inserm, CHU Lille, U1286- INFINITE- Institute for Translational Research in Inflammation, University of Lille, Lille, France.
- Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.
- The Dr Henry J Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Gastroenterology, Centro Hospitalar São João, Porto, Portugal.
- Division Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: David Rubin, Laurent Peyrin-Biroulet
Zitieren
APA
Wils, P., Jairath, V., Sands, B. E., Magro, F., Reinisch, W., Rubin, D., Danese, S., Baumann, C., & Peyrin-Biroulet, L. (2023). Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12455
Vancouver
Wils P, Jairath V, Sands BE, Magro F, Reinisch W, Rubin D, et al. Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United European Gastroenterology Journal. 2023. doi:10.1002/ueg2.12455
BibTeX
@article{Wils2023,
author = {Wils, Pauline and Jairath, Vipul and Sands, Bruce E and Magro, Fernando and Reinisch, Walter and Rubin, David and Danese, Silvio and Baumann, Cédric and Peyrin-Biroulet, Laurent},
title = {Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease},
journal = {United European Gastroenterology Journal},
year = {2023},
doi = {10.1002/ueg2.12455}
}
EUVIMED